Evidence map›Paper›PMID 35954169›Full record

ArticleCells2022

Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Chronic Lymphocytic Leukemia In Vivo.

Ekaterina Guzev, Suchita Suryakant Jadhav, Eleonora Ela Hezkiy, Michael Y Sherman, Michael A Firer, Svetlana Bunimovich-Mendrazitsky

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ekaterina GuzevDepartment of Mathematics, Ariel University, Ariel 4070000, Israel.
Suchita Suryakant JadhavDepartment of Chemical Engineering, Ariel University, Ariel 4070000, Israel.ORCID 0000-0002-6565-8335
Eleonora Ela HezkiyDepartment of Molecular Biology, Ariel University, Ariel 407000, Israel.ORCID 0000-0003-3594-6245
Michael Y ShermanDepartment of Molecular Biology, Ariel University, Ariel 407000, Israel.ORCID 0000-0001-7392-320X
Michael A FirerDepartment of Chemical Engineering, Ariel University, Ariel 4070000, Israel.ORCID 0000-0002-8430-0486
Svetlana Bunimovich-MendrazitskyDepartment of Mathematics, Ariel University, Ariel 4070000, Israel.ORCID 0000-0001-5280-3217
Ariel University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, mathematical models have developed into an important tool for cancer research, combining quantitative analysis and natural processes. We have focused on Chronic Lymphocytic Leukemia (CLL), since it is one of the most common adult leukemias, which remains incurable. As the first step toward the mathematical prediction of in vivo drug efficacy, we first found that logistic growth best described the proliferation of fluorescently labeled murine A20 leukemic cells injected in immunocompetent Balb/c mice. Then, we tested the cytotoxic efficacy of Ibrutinib (Ibr) and Cytarabine (Cyt) in A20-bearing mice. The results afforded calculation of the killing rate of the A20 cells as a function of therapy. The experimental data were compared with the simulation model to validate the latter's applicability. On the basis of these results, we developed a new ordinary differential equations (ODEs) model and provided its sensitivity and stability analysis. There was excellent accordance between numerical simulations of the model and results from in vivo experiments. We found that simulations of our model could predict that the combination of Cyt and Ibr would lead to approximately 95% killing of A20 cells. In its current format, the model can be used as a tool for mathematical prediction of in vivo drug efficacy, and could form the basis of software for prediction of personalized chemotherapy.

Indexed as

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellAnimalsComputer SimulationCytarabineMiceModels, TheoreticalAntineoplastic AgentsCytarabineA20 cellscytotoxicity ratein vivo experimentslogistic cancer growth ratemathematical modelpersonalized chemotherapystability analysistumor dynamic

Identifiers

PMID35954169
PMCPMC9367352
OpenAlexW4288443330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.